Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

1996 • 1,393 citations

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

1998 • 1,086 citations

c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer

1994 • 981 citations

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1992 • 855 citations

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1992 • 769 citations

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

1990 • 602 citations

HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.

1995 • 599 citations

Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

1996 • 564 citations

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.

1993 • 517 citations

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1993 • 501 citations

Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

1994 • 495 citations

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

1992 • 466 citations

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.

1998 • 435 citations

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

1996 • 423 citations

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

1992 • 387 citations

The addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2-overexpressing metastatic breast cancer (HER2+ MBC) markedly increases anti-cancer activity: A randomized, multinational controlled phase II trial.

1998 • 366 citations

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1997 • 344 citations

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.

1998 • 336 citations

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.

1992 • 318 citations

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

1995 • 312 citations

Follow-up study of HER-2/neu amplification in primary breast cancer.

1991 • 268 citations

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1994 • 250 citations

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.

1997 • 250 citations

The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer.

1994 • 246 citations

c-erbB-2 oncoprotein expression in primary and advanced breast cancer

1991 • 245 citations

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

1994 • 212 citations

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

1995 • 181 citations

Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure

1990 • 147 citations

Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: Correlation with steroid receptors

1992 • 123 citations

Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.

1993 • 115 citations

Analysis of gene amplification in archival tissue by differential polymerase chain reaction.

1992 • 87 citations

P46 15 year update of the naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and Tamoxifen efficacy

1998 • 79 citations

Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases

1992 • 66 citations

Advances in DNA diagnostics

1998 • 28 citations

Cited By (0)

Loading...